AEYMX
Price
$19.49
Change
-$0.67 (-3.32%)
Updated
Jul 2 closing price
Net Assets
1.89B
VEMIX
Price
$37.17
Change
-$0.17 (-0.46%)
Updated
Jul 2 closing price
Net Assets
162.82B
Interact to see
Advertisement

AEYMX vs VEMIX

AEYMX vs VEMIX Comparison Chart in %
View a ticker or compare two or three
VS
AEYMX vs. VEMIX commentary
Jul 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AEYMX is a Hold and VEMIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEMIX has more cash in the bank: 163B vs. AEYMX (1.89B). VEMIX pays higher dividends than AEYMX: VEMIX (2.31) vs AEYMX (1.07). AEYMX was incepted earlier than VEMIX: AEYMX (9 years) vs VEMIX (26 years). AEYMX (0.91) is less costly to investors than VEMIX (0.06). AEYMX is a more actively managed with annual turnover of: 58.00 vs. VEMIX (6.00). AEYMX has a lower initial minimum investment than VEMIX: AEYMX (0) vs VEMIX (5000000). AEYMX annual gain was more profitable for investors over the last year : 51.46 vs. VEMIX (20.29). AEYMX return over 5 years is better than : 34.75 vs. VEMIX (21.53).
AEYMXVEMIXAEYMX / VEMIX
Total Expense Ratio0.910.061,517%
Annual Report Gross Expense Ratio0.910.061,517%
Fund Existence9 years26 years-
Gain YTD27.7209.666287%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.89B163B1%
Annual Yield % from dividends1.072.3146%
Returns for 1 year51.4620.29254%
Returns for 3 years98.3552.80186%
Returns for 5 years34.7521.53161%
Returns for 10 yearsN/A97.80-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LBWAX23.700.31
+1.33%
BrandywineGLOBAL Div US Large Value A
EPLMX25.480.18
+0.71%
NYLI Epoch U.S. Equity Yield SIMPLE Cl
CSSZX26.78-0.16
-0.59%
Columbia Select Small Cap Value Inst
MFEJX193.29-1.40
-0.72%
MFS Growth R4
FRSIX15.93-0.22
-1.36%
Franklin Small-Mid Cap Growth C